Articles by Patricia Van Arnum - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Patricia Van Arnum

The New Normal In Biotech Financing

Financing to biotech companies in North American and Europe declined in 2012 as debt funding decreased and the IPO market remained weak.
May 3, 2013

Financing to biotech companies in North American and Europe declined in 2012 as debt funding decreased and the IPO market remained weak.

Big Pharma's Investment in Biologics

Bristol-Myers Squibb, Novartis, GlaxoSmithKline, Sanofi, and Roche are among the companies expanding biologic-based manufacturing capacity.
May 3, 2013

Bristol-Myers Squibb, Novartis, GlaxoSmithKline, Sanofi, and Roche are among the companies expanding biologic-based manufacturing capacity.

Academic and Public Partnerships in Solid-State Chemistry

Solid-state chemistry is an important part of drug development, and public research is advancing the field.
May 2, 2013

Solid-state chemistry is an important part of drug development, and public research is advancing the field.

Using Thermal Ink-Jet Printing Technology to Produce Pharmaceutical Cocrystals

Cocrystals are used to improve the performance of APIs that have non-ideal physiochemical properties.
May 2, 2013

Cocrystals are used to improve the performance of APIs that have non-ideal physiochemical properties by cocrystallizing the API with a second compound that modulates the API to provide a way to improve a drug's bioavailability, stability, and processability.

Intellectual Property Battles in Solid-State Chemistry

The rejection by India's Supreme Court on Novartis' Glivec/Gleevec (imatinib mesylate) and other recent case law raise important issues on patent strategies for solid forms.
May 2, 2013

The rejection by India's Supreme Court on Novartis' Glivec/Gleevec (imatinib mesylate) and other recent case law raise important issues on patent strategies for solid forms.

Big Pharma's Manufacturing Investments in Biologics

Despite overall manufacturing rationalization in the pharmaceutical/biopharmaceutical industry, the large pharmaceutical companies continue to invest in biologic-based manufacturing.
May 1, 2013

Despite overall manufacturing rationalization in the pharmaceutical/biopharmaceutical industry, the large pharmaceutical companies continue to invest in biologic-based manufacturing. The author provides an update in recent investment activity among the pharmaceutical majors in biologic-drug substance, vaccine, and parenteral drug manufacturing.

Delivering Complex Drugs With Nanotechnology-Based Solutions

Parenteral drug delivery offers a variety of challenges but also opportunities.
May 1, 2013

Parenteral drug delivery offers a variety of challenges but also opportunities. The author examines recent developments in nanotechnology-based drug delivery and other advances in injection-based drug delivery.

Bristol-Myers Squibb Plans Expansion of Massachusetts Biologics Facility

The company expands to add process-development and clinical-manufacturing capabilities at its large-scale bulk biologics facility.
Apr 12, 2013

The company expands to add process-development and clinical-manufacturing capabilities at its large-scale bulk biologics facility.

State Legislatures Become Battlegrounds for Biosimilars

Maryland is the latest state to consider whether to include additional requirements for substitution of biological products.
Apr 11, 2013

Maryland is the latest state to consider whether to include additional requirements for substitution of biological products

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
29%
Attracting a skilled workforce
26%
Obtaining/maintaining adequate financing
13%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
FindPharma Custom Search
Click here